Surgical Treatment of Gastric Gastrointestinal Stromal Tumor.
- Author:
Seong Ho KONG
1
;
Han Kwang YANG
Author Information
- Publication Type:Review
- Keywords: Gastrointestinal stomal tumors; Surgery; Laparoscopy; Neoadjuvant therapy
- MeSH: Benzamides; Biopsy; Esophagogastric Junction; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Hemorrhage; Incidence; Laparoscopy; Lymph Node Excision; Mucous Membrane; Neoadjuvant Therapy; Piperazines; Pyrimidines; Rupture; Seeds; Stomach; Imatinib Mesylate
- From:Journal of Gastric Cancer 2013;13(1):3-18
- CountryRepublic of Korea
- Language:English
- Abstract: Gastrointestinal stromal tumor is the most common mesenchymal tumor in the gastrointestinal tract and is most frequently developed in the stomach in the form of submucosal tumor. The incidence of gastric gastrointestinal stromal tumor is estimated to be as high as 25% of the population when all small and asymptomatic tumors are included. Because gastric gastrointestinal stromal tumor is not completely distinguished from other submucosal tumors, a surgical excisional biopsy is recommended for tumors >2 cm. The surgical principles of gastrointestinal stromal tumor are composed of an R0 resection with a normal mucosa margin, no systemic lymph node dissection, and avoidance of perforation, which results in peritoneal seeding even in cases with otherwise low risk profiles. Laparoscopic surgery has been indicated for gastrointestinal stromal tumors <5 cm, and the indication for laparoscopic surgery is expanded to larger tumors if the above mentioned surgical principles can be maintained. A simple exogastric resection and various transgastric resection techniques are used for gastrointestinal stromal tumors in favorable locations (the fundus, body, greater curvature side). For a lesion at the gastroesophageal junction in the posterior wall of the stomach, enucleation techniques have been tried preserve the organ's function. Those methods have a theoretical risk of seeding a ruptured tumor, but this risk has not been evaluated by well-designed clinical trials. While some clinical trials are still on-going, neoadjuvant imatinib is suggested when marginally unresectable or multiorgan resection is anticipated to reduce the extent of surgery and the chance of incomplete resection, rupture or bleeding.
